A Molecular Mechanism Regulating Circadian Expression of Vascular Endothelial Growth Factor in Tumor Cells

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7277-7283

  Koyanagi, Satoru ^a   Kuramoto, Yukako ^a   Nakagawa, Hiroo ^b   Aramaki, Hironori ^c   Ohdo, Shigehiro ^b   Soeda, Shinji ^a   Shimeno, Hiroshi ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c DAIICHI UNIVERSITY OF PHARMACY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; MARIMASTAT; SU 1498; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOREGULATION; BMAL1 GENE; CANCER GRAFT; CIRCADIAN RHYTHM; CLOCK GENE; CONTROLLED STUDY; CRYPTOCHROME GENE; CRYPTOCHROME1 GENE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEEDBACK SYSTEM; GENE; GENETIC ANALYSIS; HYPOXIA; MALE; METASTASIS; MOLECULAR CLOCK; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSCILLATOR; PERIOD GENE; PERIOD2 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR INDUCED ANGIOGENESIS; VEGF GENE;

ANGIOGENESIS INHIBITORS; ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CELL CYCLE PROTEINS; CELL HYPOXIA; CIRCADIAN RHYTHM; DNA-BINDING PROTEINS; DROSOPHILA PROTEINS; EYE PROTEINS; FLAVOPROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED ICR; NUCLEAR PROTEINS; PHOTORECEPTORS, INVERTEBRATE; PROMOTER REGIONS (GENETICS); RECEPTORS, ARYL HYDROCARBON; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0242610853     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Folkman, J., and Shing, Y. Angiogenesis. J. Biol. Chem., 267: 10931-10934, 1992.
2. Klagsbrun, M., and D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol., 53: 217-239, 1991.
3. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
4. Dvorak, H. F., Sioussat, T. M., Brown, L. F., Berse, B., Nagy, J. A., Sotrel, A., Manseau, E. J., Van de Water, L., and Senger, D. R. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J. Exp. Med., 174: 1275-1278, 1991.
5. Asano, M., Yukita, A., Matsumoto, T., Kondo, S., and Suzuki, H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res., 55: 5296-5301, 1995.
6. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (Wash. DC). 255: 989-991, 1992.
7. Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun., 187: 1579-1586, 1992.
8. Levy, A. P., Levy, N. S., Wegner, S., and Goldberg, M. A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem., 270: 13333-13340, 1995.
9. O'Reilly, M. S. The combination of angiogenic therapy with other modalities. Cancer J., volume 8(Suppl. 1): S89-S99, 2002.
10. Koyanagi, S., Ohdo, S., Yukawa, E., and Higuchi, S. Chronopharmacological study of interferon-α in mice. J. Pharmacol. Exp. Ther., 283: 259-264, 1997.
11. Koyanagi, S., Nakagawa, H., Kuramoto, Y., Ohdo, S., Soeda, S., and Shimeno, H. Optimizing the dosing schedule of TNP-470 [O-(chloroacetyl-carbamoyl)fumagillol] enhances its antitumor and antiangiogenic efficacies. J. Pharmacol. Exp. Ther., 304: 669-674, 2003.
12. Ohdo, S., Koyanagi, S., Suyama, H., Higuchi, S., and Aramaki, H. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat. Med., 7: 356-360, 2001.
13. Moore, R. Y., and Eichler, V. B. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. Brain Res., 42: 201-206, 1972.
14. Gekakis, N., Staknis, D., Nguyen, H. B., Davis, F. C., Wilsbacher, L. D., King, D. P., Takahashi, J. S., and Weitz, C. J. Role of the CLOCK protein in the mammalian circadian mechanism. Science (Wash. DC), 280: 1564-1569, 1998.
15. Kume, K., Zylka, M. J., Sriram, S., Shearman, L. P., Weaver, D. R., Jin, X., Maywood, E. S., Hastings, M. H., and Reppert, S. M. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell, 98: 193-205, 1999.
16. Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler, W. R., Longhi, M. P., Hui, T. H., Tang, C., Levitzki, A., Gazit, A., Chen, I., Keri, G., Orfi, L., Risau, W., Flamme, I., Ullrich, A., Hirth, K. P., and Shawver, L. K. FIk-1 as a target for tumor growth inhibition. Cancer Res., 56: 3540-3545, 1996.
17. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (Lond.), 348: 555-557, 1990.
18. Watson, S. A., Morris, T. M., Collins, H. M., Bawden, L. J., Hawkins, K., and Bone, E. A. Inhibition of tumor growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br. J. Cancer, 81: 19-23, 1999.
19. Pando, M. P., Morse, D., Cermakian, N., and Sassone-Corsi, P. Phenotypic rescue of a peripheral clock genetic defect via SCN hierarchical dominance. Cell, 110: 107-117, 2002.
20. Lee, C., Etchegaray, J. P., Cagampang, F. R., Loudon, A. S., and Reppert, S. M. Posttranslational mechanisms regulate the mammalian circadian clock. Cell, 107: 855-867, 2001.
21. Preitner, N., Damiola, F., Molina, L. L., Zakany, J., Duboule, D., Albrecht, U., and Schibler, U. The orphan nuclear receptor REV-ERBα controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell, 110: 251-260, 2002.
22. Zylka, M. J., Shearman, L. P., Weaver, D. R., and Reppert, S. M. Three period homologs in mammals: differential light responses in the suprachiasmatic circadian clock and oscillating transcripts outside of brain. Neuron. 20: 1103-1110, 1998.
23. Ferrara, N., and Davis-Smith, T. The biology of vascular endothelial growth factor. Endocr. Rev., 18: 4-25, 1997.
24. Hogenesch, J. B., Gu, Y. Z., Jain, S., and Bradfield, C. A. The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. Proc. Natl. Acad. Sci. USA, 95: 5474-5479, 1998.
25. Hogenesch, J. B., Gu, Y. Z., Moran, S. M., Shimomura, K., Radcliffe, L. A., Takahashi, J. S., and Bradfield, C. A. The basic helix-loop-helix-PAS protein MOP9 is a brain-specific heterodimeric partner of circadian and hypoxia factors. J. Neurosci., 20: RC83, 2000.
26. Kimura, H., Weisz, A., Ogura, T., Hitomi, Y., Kurashima, Y., Hashimoto, K., D'Acquisto, F., Makuuchi, M., and Esumi, H. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J. Biol. Chem., 276: 2292-2298, 2000.
27. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Wash. DC), 246: 1306-1309, 1989.
28. Wang, H., and Keiser, J. A. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of fit-1. Circ. Res., 83: 832-840, 1998.
29. 2 tension. Proc. Natl. Acad. Sci. USA, 92: 5510-5514, 1995.
30. Reyes, H., Reisz-Porszasz, S., and Hankinson, O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science (Wash. DC), 256: 1193-1195, 1992.
31. Zheng, B., Larkin, D. W., Albrecht, U., Sun, Z. S., Sage, M., Eichele, G., Lee, C. C., and Bradley, A. The mPer2 gene encodes a functional component of the mammalian circadian clock. Nature (Lond.), 400: 169-173, 1999.
32. Chilov, D., Hofer, T., Bauer, C., Wenger, R. H., and Gassmann, M. Hypoxia affects expression of circadian genes PER1 and CLOCK in mouse brain. FASEB J., 15: 2613-2622, 2001.
33. Shearman, L. P., Zylka, M. J., Weaver, D. R., Kolakowski, L. F., Jr., and Reppert, S. M. Two period homologs: circadian expression and photic regulation in the suprachiasmatic nuclei. Neuron, 19: 1261-1269, 1997.
34. Etchegaray, J. P., Lee, C., Wade, P. A., and Reppert, S. M. Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature (Lond.). 421: 177-182, 2003.
35. Kallio, J. P., Okamoto, K., O'Brien, S., Carrero, P., Makino, Y., Tanaka, H., and Poellinger, L. Signal transduction of hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1a. EMBO J., 17: 6573-6586, 1998.
36. Pluda, J. M. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin. Oncol., 24: 203-218, 1997.
37. Endo, I., Mitsui, T., Nishino, M., Oshima, Y., and Matsumoto, T. Diurnal fluctuation of edema synchronized with plasma VEGF concentration in a patient with POEMS syndrome. Intern. Med., 41: 1196-1198, 2002.